The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreOct 2019
US$990Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
A number of dermatological products have traditionally been surrounded by social stigma, for example vaginal and topical antifungals or haemorrhoid treatments. However, it would seem the stigma attached to these products is gradually being eroded, with antifungals holding the largest value share within dermatologicals (combining topical and vaginal) and haemorrhoid treatments the most dynamic category in 2019.
There is increasing diagnosis of skin diseases in Colombia, with experts stating that atopic dermatitis has become one of the diseases that most Colombians suffer from in terms of dermatological problems. It is estimated that between 5% and 10% of the Colombian population may be affected by this chronic condition.
Although the birth rate is declining in Colombia, it is still relatively high, standing at 14.4 births per 1,000 population in 2019.
Genomma Lab continued to lead dermatologicals in 2019, with its main brands including Medicasp, Lomecan and Unesia. Genomma Lab continued to run strong advertising campaigns, increasingly tapping into the social media channel.
A number of players were continuing to use social media as a major advertising and promotional channel at the end of the review period. For example, Genomma Lab’s Lomecan in vaginal antifungals again benefited from a strong campaign and presence on social networks.
Private label remains undeveloped in dermatologicals. Only topical antifungals and topical germicidals/antiseptics have a private label presence, but, even in these categories, branded products continued to dominate value sales.
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
Delivery: Files are delivered directly into your account within a few minutes of purchase.
Overview
Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Colombia with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Medicated Skin Care industry in Colombia, our research will save you time and money while empowering you to make informed, profitable decisions.
The Medicated Skin Care in Colombia market research report includes:
Our market research reports answer questions such as:
Why buy this report?
This industry report originates from Passport, our Consumer Health market research database.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.